Adverum Biotechnologies Inc (ADVM) Stock
ADVM is no longer traded. Adverum Biotechnologies was delisted from the Nasdaq in December 2025.
Prices on this page are historical; the last trade was December 8, 2025 at $4.36.
Adverum Biotechnologies stock price history
ADVM final trading statistics
- Final close
- $4.36
- Final trading day
- Dec 8, 2025
- Market cap at delisting
- $96.26M
- Shares outstanding
- 22.08M
- Final 52-week range
- $1.78 – $6.12
- Avg. volume (final 3 mo.)
- 716,504
- All-time high (split-adj.)
- $600.80 · Jan 2015
- All-time low (split-adj.)
- $2.05 · May 2025
- Return since IPO
- -98.4%
- Beta
- 0.87
- Book value / share
- -$2.53
- Price / book
- -1.72
Adverum Biotechnologies annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $1.00M | -$130.9M | -$5.65 |
| FY2023 | $3.60M | -$122.1M | -$3.23 |
| FY2022 | $3.60M | -$154.5M | -$1.55 |
| FY2021 | $7.50M | -$145.5M | -$1.48 |
| FY2020 | $7.50M | -$117.5M | -$1.37 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Adverum Biotechnologies stock FAQ
What happened to Adverum Biotechnologies stock?
Adverum Biotechnologies stock was delisted from the Nasdaq. Its final close was $4.36 on December 8, 2025.
Is ADVM stock still trading?
No. ADVM was delisted from the Nasdaq in December 2025 and no longer trades on a U.S. exchange.
What was the last price of ADVM stock?
ADVM closed at $4.36 on its final trading day, December 8, 2025, for a market value of about $96.26M.
What were Adverum Biotechnologies's revenue and earnings in its last full fiscal year?
Adverum Biotechnologies reported revenue of $1.00M and net income of -$130.9M in fiscal 2024, its last full year as a public company.
When did Adverum Biotechnologies go public?
Adverum Biotechnologies Inc stock began trading on July 31, 2014.